#oncotarget

[chrissines]

[rnomics]

Long non-coding #RNA XIST as a potential prognostic biomarker in human #cancers: a meta-analysis.

Long non-coding #RNA XIST as a potential prognostic biomarker in human #cancers: a meta-analysis. Oncotarget. 2018 Mar 02;9(17):13911-13919 Authors: Hu S, Chang J, Li Y, Wang W, Guo M, Zou EC, Wang Y, Yang Y Abstract Growing studies have confirmed that long non-coding #RNAs (l#ncRNAs) involve in the occurrence and development of various #cancers. XIST, as a l#ncRNA, was dysregulated in different #cancers. This meta-analysis was performed to evaluate the prognostic potential of XIST in malignant tumors. Eight databases of PubMed, Web of Science, Embase, Cochrane library, CNKI, VIP, SinoMed and Wang Fang were comprehensively searched from their initiation date to August 15, 2017. A total of nine studies with 853 #cancer patients met the including criteria were finally included in this meta-analysis after independently screening the literatures by two researchers. Any discrepancies were resolved by a consensus. Hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) for the primary endpoints were extracted and pooled for meta-analysis. Our results showed that expression level of XIST was markedly associated with overall survival (function as oncogene, HR = 0.53, 95% CI: 0.42-0.68, p < 0.00001; function as tumor suppressor, HR = 2.25, 95% CI: 1.15-4.37, p = 0.02), disease free survival (DFS)(HR = 0.45; 95% CI: 0.31-0.67, p < 0.0001), tumor type (digestive system carcinoma, HR = 0.50; 95% CI: 0.37-0.69, p < 0.00001; non-digestive system carcinoma, HR = 0.58; 95% CI: 0.39-0.87, p = 0.008), lymph node metastasis (OR = 0.32, 95% CI: 0.20-0.52, p < 0.00001), distant metastasis (OR = 0.36, 95% CI: 0.22-0.60, p < 0.0001) and tumor stage (OR = 0.43, 95% CI: 0.31-0.60, p < 0.00001). In conclusion, the pooled results in our current work suggest that XIST is an important prognostic biomarker in #cancer patients. PMID: 29568404 [PubMed] http://bit.ly/2pBbxJQ #Pubmed

[rnomics]

Prognostic role of long noncoding #RNA ZFAS1 in #cancer patients: a systematic review and meta-analysis.

Related Articles Prognostic role of long noncoding #RNA ZFAS1 in #cancer patients: a systematic review and meta-analysis. Oncotarget. 2017 Nov 21;8(59):100490-100498 Authors: Lan T, Lan X, Li G, Zheng Z, Zhang M, Qin F Abstract Long noncoding #RNA ZFAS1 has been identified as a crucial role in the tumorigenesis of malignant tumors. Numerous studies reported that the expression levels of ZFAS1 in tumor tissues were dramatically higher than that in adjacent normal tissues. We conducted a meta-analysis to investigate the correlation between ZFAS1 expression and clinical outcomes of #cancer patients. The databases of PubMed, EMBASE, Web of Science, Cochrane Library, CNKI and WanFang were retrieved for eligible studies. A total of 841 patients from 9 studies were eventually included. Our results demonstrated that increased ZFAS1 expression was significantly associated with poor OS in #cancer patients (HR = 2.13, 95% CI = 1.71-2.65, P < 0.001). Patients with high ZFAS1 expression presented shorter RFS than those with low ZFAS1 expression (HR = 2.00, 95% CI = 1.45-2.77, P < 0.001). The clinicopathological parameters analysis demonstrated that increased ZFAS1 expression was significantly associated with vascular invasion (OR = 2.26, 95% CI = 1.36-3.78, P = 0.002), lymph node metastasis (OR = 2.98, 95% CI = 2.12-4.19, P < 0.001) and advanced TNM stage (OR = 3.00, 95% CI = 2.18-4.12, P < 0.001). In conclusion, l#ncRNA ZFAS1 might serve as a prognostic biomarker for #cancer patients and increased ZFAS1 expression may be closely related to advanced characteristics of #cancer. PMID: 29245995 [PubMed] http://bit.ly/2oEWGzO #Pubmed

[rnomics]

Long non-coding #RNA TUG1 as a potential prognostic biomarker in human #cancers: a meta-analysis.

Long non-coding #RNA TUG1 as a potential prognostic biomarker in human #cancers: a meta-analysis. Oncotarget. 2017 Sep 22;8(37):62454-62462 Authors: Ma PJ, Guan QK, Meng L, Qin N, Zhao J, Jin BZ Abstract L#ncRNA taurine upregulated gene 1 (TUG1) is reportedly dysregulated in various #cancers. We performed this meta-analysis to clarify the usefulness of TUG1 as a prognostic marker in malignant tumors. The PubMed, Medline, OVID, Cochrane Library, and Web of Science databases were searched from inception to Jan 11, 2017. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated to explore the relationship between TUG1 expression and overall survival (OS). Odds ratios (ORs) were calculated to assess the association between TUG1 expression and pathological parameters. Thirteen original studies covering 1,274 #cancer patients were included in this meta-analysis. The pooled HR suggested that high TUG1 expression correlated with poor OS (pooled HR=1.41, 95% CI: 1.01-1.98) in #cancer types other than non-small cell lung #cancer. TUG1 expression was also related to distant metastasis (OR=3.24, 95% CI: 1.18-8.93), large tumor size (OR=4.07, 95% CI: 1.08-15.28) and advanced tumor stage (OR=3.45, 95% CI: 2.19-5.44). Begg's funnel plot and Egger's test showed no evidence of obvious asymmetry for overall survival or tumor stage. Thus high TUG1 expression appears predictive of poor OS, distant metastasis, advanced tumor stage and large tumor size. This suggests TUG1 expression could serve as a biomarker for poor prognosis in #cancers. PMID: 28977959 [PubMed] http://bit.ly/2geI4R5 #Pubmed

[rnomics]

Prognostic value of decreased long non-coding #RNA TUSC7 expression in some solid tumors: a systematic review and meta-analysis.

Prognostic value of decreased long non-coding #RNA TUSC7 expression in some solid tumors: a systematic review and meta-analysis. Oncotarget. 2017 Aug 29;8(35):59518-59526 Authors: Li N, Yang M, Shi K, Li W Abstract Accumulating evidences indicated that tumor suppressor candidate 7 (TUSC7) is a putatively tumor suppressor gene in various tumors. We carried out current systematic review and meta-analysis to explore the decreased expression of TUSC7 associate with prognostic and clinicopathological characteristic in #cancer patients. A literature collection search in the online electronic databases PubMed, Embase, Web of Science, and CNKI was conducted to obtain eligible studies (up to February 20, 2017). A total of nine studies comprise 757 patients were identified and included in present meta-analysis based on the selection and inclusion criteria. Overall, low expression of TUSC7 was associated with significantly unfavorable overall survival (OS) (HR = 2.90, 95% CI: 2.12-3.98, P < 0.001), disease free survival (DFS) (HR = 2.00, 95% CI: 1.49-2.68, P < 0.001) and disease-specific survival (DSS) (HR = 2.57, 95% CI: 1.23-5.39, P = 0.012) in tumors patients. Moreover, we also found that down-regulation of TUSC7 associated with distant metastasis (OR = 2.85, 95% CI: 1.46-5.55, P = 0.002) and larger tumor size (OR = 0.41, 95% CI: 0.23-0.72, P = 0.002). Our meta-analysis demonstrated that #cancers patients detected with low TUSC7 expression were more prone to develop distant metastasis. TUSC7 might act as a potentially and promising common prognostic markers in some solid tumors. PMID: 28938655 [PubMed - in process] http://bit.ly/2xnuy7x #Pubmed

[rnomics]

Long non-coding #RNA HULC as a potential prognostic biomarker in human #cancers: a meta-analysis.

Long non-coding #RNA HULC as a potential prognostic biomarker in human #cancers: a meta-analysis. Oncotarget. 2017 Feb 10;: Authors: Fan YH, Wu MJ, Jiang Y, Ye M, Lu SG, Wu L, Zhu XG Abstract Since the long non-coding #RNA HULC (Highly Upregulated in Liver #cancer) is dysregulated in many #cancers, we performed a meta-analysis to determine its prognostic potential in malignant tumors. We searched electronic databases, including PubMed, Medline, OVID, Cochrane Library and Web of Science from inception until August 14, 2016 and identified seven studies with 730 #cancer patients for the meta-analysis. We analyzed the hazard ratios (HRs) and 95% confidence intervals (CIs) to determine the relationship between HULC expression and overall survival (OS). We also using RevMan5.3 software to calculate odds ratio (ORs) to assess the association between HULC expression and pathological parameters, including lymph node metastasis (LNM), distant metastasis (DM) and the tumor stage. Our analysis showed that higher HULC expression was associated with OS (HR= 0.50, 95% CI: 0.35-0.70, P http://bit.ly/2lV1N92 #Pubmed

[rnomics]

Long noncoding #RNA MEG3, a potential novel biomarker to predict the clinical outcome of #cancer patients: a meta-analysis.

Related Articles Long noncoding #RNA MEG3, a potential novel biomarker to predict the clinical outcome of #cancer patients: a meta-analysis. Oncotarget. 2017 Feb 01;: Authors: Cui X, Jing X, Long C, Tian J, Zhu J Abstract Numerous studies have demonstrated that the expression level of maternally expressed gene 3 (MEG3) was lost in various #cancers. Low expression of MEG3 is associated with an increased risk of metastasis and a poor prognosis in #cancer patients. This meta-analysis investigated the association between MEG3 levels and distant metastasis (DM), lymph node metastasis (LNM), overall survival (OS), and recurrence-free survival (RFS) of #cancer patients. A total of 536 participants from 9 articles were finally enrolled. The results showed a significant negative association between MEG3 levels and DM (OR = 2.16, 95% CI = 0.99-4.71, P = 0.05, fixed-effect), and it could also predict poor OS (HR = 0.43, 95% CI = 0.15-1.24, P = 0.006, fixed-effect) and RFS (HR = 0.52, 95% CI = 0.29-0.92, P = 0.02, fixed-effect) in #cancer patients. In conclusion, this meta-analysis indicated that MEG3 might serve as a potential novel biomarker for indicating the clinical outcomes in human #cancers. PMID: 28157702 [PubMed - as supplied by publisher] http://bit.ly/2laslqx #Pubmed

[rnomics]

Circulating thyroid stimulating hormone receptor messenger #RNA and differentiated thyroid #cancer: A diagnostic meta-analysis.

Circulating thyroid stimulating hormone receptor messenger #RNA and differentiated thyroid #cancer: A diagnostic meta-analysis. Oncotarget. 2016 Dec 27;: Authors: Zhang ZZ, Chen Q, Kong CY, Li ZM, Wang LS Abstract Thyroid stimulating hormone receptor messenger #RNA (TSHR-#mRNA) is over-expressed in thyroid #cancer patients, which indicates that TSHR-#mRNA is a potential biomarker of thyroid #cancer. However, system evaluation for TSHR-#mRNA as a diagnostic biomarker of thyroid #cancer is deficient. The performance of TSHR-#mRNA for thyroid #cancer diagnosis was evaluated in this study. Three common international databases as well as a Chinese database were applied for literature researching. Quality assessment of the included literatures was conducted by the QUADAS-2 tool. Totally, 1027 patients from nine studies eligible for the meta-analysis were included in this study. Global sensitivity and specificity for the positivity of TSHR-#mRNA in the thyroid #cancer diagnosis is 72% and 82%. The value of AUC for this test performance was 0.84. Our meta-analysis suggests that TSHR-#mRNA might be a potential biomarker to complete present diagnostic methods for early and precision diagnosis of thyroid #cancer. Notably, this findings need validation thorough large-scale clinical studies. PMID: 28036261 [PubMed - as supplied by publisher] http://bit.ly/2hW6nlA #Pubmed